|
"wu s g"的相關文件
顯示項目 191-200 / 224 (共23頁)
<< < 14 15 16 17 18 19 20 21 22 23 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2020-03-05T08:04:02Z |
A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population
|
Gow C.-H.;Min-Shu Hsieh;Wu S.-G.;Shih J.-Y.; Gow C.-H.; MIN-SHU HSIEH; Wu S.-G.; Shih J.-Y. |
| 國立成功大學 |
2020 |
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
|
Wu, S.-G.;Chiang, Chiang C.-L.;Liu, C.-Y.;Wang, C.-C.;Su, P.-L.;Hsia, T.-C.;Shih, J.-Y.;Chang, G.-C. |
| 臺大學術典藏 |
2019 |
MicroRNA in lung cancer metastasis
|
Wu S.-G.;Chang T.-H.;Liu Y.-N.;Jin-Yuan Shih; Wu S.-G.; Chang T.-H.; Liu Y.-N.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2018-09-10T15:17:15Z |
Treatment outcome of patients with isoniazid mono-resistant tuberculosis
|
Yu, C. -J.; Wang, J. -Y.; Lee, J. -J.; Chien, J. -Y.;Chen, Y. -T.;Wu, S. -G.;Lee, J. -J.;Wang, J. -Y.;Yu, C. -J.; Chien, J.-Y. and Chen, Y.-T. and Wu, S.-G. and Lee, J.-J. and Wang, J.-Y. and Yu, C.-J.; 余忠仁;吳尚俊;王振源;簡榮彥; Chien, J. -Y.; Chong-Jen Yu; JANN-YUAN WANG; Chen, Y. -T.; Wu, S. -G.; JUNG-YIEN CHIEN |
| 臺大學術典藏 |
2018-09-10T09:13:23Z |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
|
Tsai, T.-H. and Su, K.-Y. and Wu, S.-G. and Chang, Y.-L. and Luo, S.-C. and Jane, I.-S. and Yu, C.-J. and Yue, S.-L. and Shih, J.-Y. and Yang, P.-C.; Tsai, T-H.;Su, K-Y.;Wu, S-G.;Chang, Y-L.;Luo, S-C.;Jan, I-S.;Yu, C-J.;Yu, S-L.;Shih, J-Y.;Yang, P-C.; 俞松良 ;詹一秀 ;張逸良 ;楊泮池 ;余忠仁 ;吳尚俊 ;蔡子修 ;施金元; Tsai, T-H.; YIH-LEONG CHANG; Tsai, T-H.; Chong-Jen Yu; Su, K-Y.; Wu, S-G.; Wu, S-G.; KANG-YI SU; JIN-YUAN SHIH; Chang, Y-L.; Luo, S-C.; Luo, S-C.; Jan, I-S.; Jan, I-S.; Yu, C-J.; Yu, S-L.; Shih, J-Y.; Shih, J-Y.; Yang, P-C.; 楊泮池 |
| 臺大學術典藏 |
2018-09-10T08:28:53Z |
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction
|
Wu, S.-G.;Chang, Y.-L.;Lin, J.-W.;Wu, C.-T.;Chen, H.-Y.;Tsai, M.-F.;Lee, Y.-C.;Yu, C.-J.;Shih, J.-Y.; CHEN-TU WU; YIH-LEONG CHANG; Chong-Jen Yu; JIN-YUAN SHIH |
| 臺大學術典藏 |
2018-09-10T07:05:53Z |
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
|
Wu, J.-Y.; Wu, S.-G.; Yang, C.-H.; Gow, C.-H.; Chang, Y.-L.; Yu, C.-J.; Shin, J.-Y.; Yang, P.-C.; YIH-LEONG CHANG; CHONG-JEN YU; PAN-CHYR YANG |
| 臺大學術典藏 |
2017 |
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
|
Wu S.-G.;Yih-Leong Chang;Yu C.-J.;Yang P.-C.;Shih J.-Y.; Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2017 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
|
Lin Y.-T.;Liu Y.-N.;Wu S.-G.;Yang J.C.-H.;Jin-Yuan Shih; Lin Y.-T.; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2017 |
A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population
|
Gow C.-H.;Hsieh M.-S.;Wu S.-G.;Jin-Yuan Shih; Gow C.-H.; Hsieh M.-S.; Wu S.-G.; JIN-YUAN SHIH |
顯示項目 191-200 / 224 (共23頁)
<< < 14 15 16 17 18 19 20 21 22 23 > >>
每頁顯示[10|25|50]項目
|
